Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 619 checkpoint-related abstracts that have been carefully screened and added to the Beacon database. Of these 619 abstracts, 612 presented clinical trial data, and the remaining 7 presented preclinical data.
The most common ICM target asset presented at ASCO 2022 was PD-1 with a total of 488 abstracts (484 clinical and 4 preclinical). Within disease indication, lung cancer and skin cancer are the most studied solid tumors at ASCO with a total of 150 abstracts. And within blood cancer indications, lymphoma and leukemia are amongst the most studied blood cancers with a total of 17 abstracts.
For more insight please download the sample, contact us, or request a demo.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements